Medicure Inc V.MPH

Enrollment complete on MC-1 trial

[newcomer21]

Medicure Completes MEND-1 Patient Enrollment WINNIPEG, Manitoba - (September 16, 2002) - Medicure Inc. (TSX:MPH) is pleased to announce the completion of patient enrollment in its multi-centre Phase II clinical trial to evaluate the cardioprotective effect of MC-1 against potential damage caused by ischemia and ischemic reperfusion frequently experienced by high risk heart disease patients undergoing angioplasty. With full enrollment, the last patient completing the study will be in four weeks, at which time the database will be locked and analysis started. "The successful completion of patient enrollment is an exciting step in the development of our lead product, MC-1," stated Albert D. Friesen, PhD, President and CEO. "This trial will expand our understanding of the cardioprotective effect of MC-1, gathering important efficacy and safety data. We look forward to analyzing the data and reporting the results by the end of the year." The Phase II trial is a placebo controlled single blind feasibility study called MEND-1. As previously announced, the study is managed by the Duke Clinical Research Institute (DCRI), Durham, North Carolina, a recognized leader in cardiovascular clinical trials, clinical drug research and the evaluation of novel therapeutics under the direction of Principal Investigator, Dr. James E. Tcheng MD, F.A.C.C. The trial enrolled 60 high-risk patients scheduled for elective percutaneous coronary intervention by angioplasty at sites in the U.S. and Canada. The primary endpoint of the trial is infarct size (area of the heart that is damaged) during the procedure as determined by the release of the cardiac enzyme CK-MB over 24 hours following angioplasty. About Medicure Inc. Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine including the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information, please contact: Derek Reimer Chief Financial Officer Medicure Inc. 888-435-2220 204-488-9823 fax [e-mail] www.medicureinc.com